Access to treatment for hepatitis C virus infection: time to put patients first.
about
Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseHepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.COST-EFFECTIVE OPTIONS FOR THE PREVENTION AND MANAGEMENT OF GASTROINTESTINAL AND LIVER DISEASE IN THE ASIA-PACIFIC REGION.Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpointMedicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.
P2860
Q33802414-EF228D6D-5F48-43DB-B4C1-7DBE908EDD27Q36240269-D02CEB5D-C992-4DFB-8DB1-EDC43929DB1CQ36306768-8A2F2B9A-71E6-4AE1-A738-1A42E93D3EDEQ37578288-1F204D83-C426-46A5-963F-70508694DA1AQ38635796-D7834619-6787-4D69-8D66-795074EF61A8Q38876302-0AEF38BD-EC8D-4A2C-B5CE-4271F03F45B2Q40054265-1E82EAD0-B31B-4987-8B99-89AE096833BAQ40078226-15C66E1F-8BC2-41C2-BA33-69D3906BBDF4Q40082765-CC33DDDF-00D1-48BB-ADB5-A67258741F7CQ42329781-08A91F16-8EB7-4C93-8367-2F07439F7451Q53381076-401161DA-DA25-48DE-B182-600164A143F1Q55163317-34DE1F28-85B0-464A-BC90-FD20CCEF938CQ55280981-7DFB139F-6167-4ADE-9BD6-2CEBAC1C01CBQ55452535-EAA8007A-E147-4D3A-B256-1CF5D477B3E6
P2860
Access to treatment for hepatitis C virus infection: time to put patients first.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Access to treatment for hepatitis C virus infection: time to put patients first.
@ast
Access to treatment for hepatitis C virus infection: time to put patients first.
@en
type
label
Access to treatment for hepatitis C virus infection: time to put patients first.
@ast
Access to treatment for hepatitis C virus infection: time to put patients first.
@en
prefLabel
Access to treatment for hepatitis C virus infection: time to put patients first.
@ast
Access to treatment for hepatitis C virus infection: time to put patients first.
@en
P1476
Access to treatment for hepatitis C virus infection: time to put patients first.
@en
P304
P356
10.1016/S1473-3099(16)30005-6
P50
P577
2016-07-12T00:00:00Z